Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder characterized by progressive muscle weakness, primarily affecting the facial, shoulder, and upper arm muscles. In this literature review, we examined the available treatments for FSHD, covering established methods and experimental approaches. We began with an overview of pharmacological treatments, emphasizing the importance of physical therapy and rehabilitation in maintaining muscle strength, improving mobility, preventing contractures, and respiratory therapy for severe cases. We also explored exercise interventions, addressing the debate surrounding exercise in FSHD patients, and highlight the possible benefits of aerobic and strength training, as well as ongoing research into safe exercise protocols. Additionally, the use of assistive devices and orthotics, such as braces and mobility aids, is discussed, along with surgical interventions like scapular fixation surgery and corrective procedures for foot drop. Emerging therapeutic strategies, including gene therapy focusing on DUX4 silencing and CRISPR-Cas9 technology, were evaluated. The potential of antisense oligonucleotides and myostatin inhibitors was reviewed, along with the challenges and ethical considerations associated with cell-based therapies. We aimed to inform researchers and advance treatment strategies for FSHD patients.
Citation: Ubaid Ansari, Dawnica Nadora, Lauren Ong, Romteen Sedighi, Ethan Tabaie, Zaid Ansari, Meraj Alam, Burhaan Syed, Noorhan Amani, Sarah Preiss-Farzanegan. Current landscape for the management of facioscapulohumeral muscular dystrophy and emerging treatment modalities: A literature review[J]. AIMS Neuroscience, 2025, 12(2): 291-311. doi: 10.3934/Neuroscience.2025016
Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder characterized by progressive muscle weakness, primarily affecting the facial, shoulder, and upper arm muscles. In this literature review, we examined the available treatments for FSHD, covering established methods and experimental approaches. We began with an overview of pharmacological treatments, emphasizing the importance of physical therapy and rehabilitation in maintaining muscle strength, improving mobility, preventing contractures, and respiratory therapy for severe cases. We also explored exercise interventions, addressing the debate surrounding exercise in FSHD patients, and highlight the possible benefits of aerobic and strength training, as well as ongoing research into safe exercise protocols. Additionally, the use of assistive devices and orthotics, such as braces and mobility aids, is discussed, along with surgical interventions like scapular fixation surgery and corrective procedures for foot drop. Emerging therapeutic strategies, including gene therapy focusing on DUX4 silencing and CRISPR-Cas9 technology, were evaluated. The potential of antisense oligonucleotides and myostatin inhibitors was reviewed, along with the challenges and ethical considerations associated with cell-based therapies. We aimed to inform researchers and advance treatment strategies for FSHD patients.
| [1] | Preston MK, Tawil R, Wang LH (1993) Facioscapulohumeral Muscular Dystrophy. GeneReviews® [Internet] . Seattle (WA): University of Washington, Seattle. |
| [2] |
Guien C, Blandin G, Lahaut P, et al. (2018) The French National Registry of patients with Facioscapulohumeral muscular dystrophy. Orphanet J Rare Dis 13: 218. https://doi.org/10.1186/s13023-018-0960-x 
|
| [3] |
van der Maarel SM, Tawil R, Tapscott SJ (2011) Facioscapulohumeral Muscular Dystrophy and DUX4: Breaking the Silence. Trends Mol Med 17: 252-258. https://doi.org/10.1016/j.molmed.2011.01.001
|
| [4] | Statland JM, Tawil R (2016) Facioscapulohumeral Muscular Dystrophy. Continuum (Minneap Minn) 22: 1916-1931. https://doi.org/10.1212/CON.0000000000000399 |
| [5] |
Corrado B, Ciardi G (2015) Facioscapulohumeral distrophy and physiotherapy: a literary review. J Phys Ther Sci 27: 2381-2385. https://doi.org/10.1589/jpts.27.2381
|
| [6] |
Himeda CL, Jones PL (2022) FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?. J Pers Med 12: 865. https://doi.org/10.3390/jpm12060865
|
| [7] |
Cohen J, DeSimone A, Lek M, et al. (2021) Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy. Trends Mol Med 27: 123-137. https://doi.org/10.1016/j.molmed.2020.09.008
|
| [8] |
Eren İ, Gedik CC, Kılıç U, et al. (2022) Management of scapular dysfunction in facioscapulohumeral muscular dystrophy: the biomechanics of winging, arthrodesis indications, techniques and outcomes. EFORT Open Rev 7: 734-746. https://doi.org/10.1530/EOR-22-0080
|
| [9] |
Tawil R, McDermott MP, Pandya S, et al. (1997) A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 48: 46-49. https://doi.org/10.1212/wnl.48.1.46
|
| [10] |
Passerieux E, Hayot M, Jaussent A, et al. (2015) Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: A double-blind randomized controlled clinical trial. Free Radical Bio Med 81: 158-169. https://doi.org/10.1016/j.freeradbiomed.2014.09.014
|
| [11] |
Maltin CA, Delday MI, Watson JS, et al. (1993) Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond) 84: 651-654. https://doi.org/10.1042/cs0840651
|
| [12] |
Lynch GS, Hayes A, Campbell SP, et al. (1996) Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J Appl Physiol (1985) 81: 1610-1618. https://doi.org/10.1152/jappl.1996.81.4.1610
|
| [13] |
Zeman RJ, Peng H, Danon MJ, et al. (2000) Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve 23: 521-528. https://doi.org/10.1002/(sici)1097-4598(200004)23:4<521::aid-mus10>3.0.co;2-8
|
| [14] |
Kissel JT, McDermott MP, Mendell JR, et al. (2001) Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57: 1434-1440. https://doi.org/10.1212/WNL.57.8.1434
|
| [15] |
van der Kooi EL, Vogels OJM, van Asseldonk RJGP, et al. (2004) Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 63: 702-708. https://doi.org/10.1212/01.WNL.0000134660.30793.1F
|
| [16] |
Payan CA, Hogrel JY, Hammouda EH, et al. (2009) Periodic Salbutamol in Facioscapulohumeral Muscular Dystrophy: A Randomized Controlled Trial. Arch Phys Med Rehabil 90: 1094-1101. https://doi.org/10.1016/j.apmr.2008.12.027
|
| [17] |
Tawil R, Wagner KR, Hamel JI, et al. (2024) Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 23: 477-486. https://doi.org/10.1016/S1474-4422(24)00073-5
|
| [18] | FSHD SocietyFulcrum halts losmapimod development (2024). [cited 2024 November 25]. Available from: https://www.fshdsociety.org/2024/09/12/fulcrum-halts-losmapimod-development/ |
| [19] | KU Medical CenterPreliminary drug trial results give hope to those with a common form of muscular dystrophy (2024). [cited 2024 November 25]. Available from: https://www.kumc.edu/about/news/news-archive/prelim-drug-trial.html |
| [20] |
Attarian S, Salort-Campana E, Nguyen K, et al. (2012) Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011. Rev Neurol (Paris) 168: 910-918. https://doi.org/10.1016/j.neurol.2011.11.008
|
| [21] |
Tawil R, Mah JK, Baker S, et al. (2016) Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscul Disord 26: 462-471. https://doi.org/10.1016/j.nmd.2016.03.007
|
| [22] |
Tawil R, Kissel JT, Heatwole C, et al. (2015) Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy. Neurology 85: 357-364. https://doi.org/10.1212/WNL.0000000000001783
|
| [23] |
Aitkens SG, McCrory MA, Kilmer DD, et al. (1993) Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 74: 711-715. https://doi.org/10.1016/0003-9993(93)90031-5
|
| [24] | Milner-Brown HS, Miller RG (1988) Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil 69: 14-19. |
| [25] |
Vignos PJ, Watkins MP (1966) The Effect of Exercise in Muscular Dystrophy. JAMA 197: 843-848. https://doi.org/10.1001/jama.1966.03110110067015
|
| [26] | Voet NB, Kooi EL van der, Engelen BG van, et al. (2019) Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev 12: CD003907. https://doi.org/10.1002/14651858.CD003907.pub5 |
| [27] | Calisgan E, Yilmaz O, Tuncel D, et al. (2019) Early adulthood onset of muscle weakness in facioscapulohumeral muscular dystrophy and physical therapy management: An unusual case report. Medicine 8: 1036-1040. https://doi.org/10.5455/medscience.2019.08.9108 |
| [28] |
Gianola S, Castellini G, Pecoraro V, et al. (2020) Effect of Muscular Exercise on Patients With Muscular Dystrophy: A Systematic Review and Meta-Analysis of the Literature. Front Neurol 11: 958. https://doi.org/10.3389/fneur.2020.00958
|
| [29] |
Bankolé LC, Millet GY, Temesi J, et al. (2016) Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophy. Medicine (Baltimore) 95: e4497. https://doi.org/10.1097/MD.0000000000004497
|
| [30] |
Olsen DB, Ørngreen MC, Vissing J (2005) Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology 64: 1064-1066. https://doi.org/10.1212/01.WNL.0000150584.45055.27
|
| [31] |
Bettio C, Banchelli F, Salsi V, et al. (2024) Physical activity practiced at a young age is associated with a less severe subsequent clinical presentation in facioscapulohumeral muscular dystrophy. BMC Musculoskelet Disord 25: 35. https://doi.org/10.1186/s12891-023-07150-x
|
| [32] |
Tawil R (2008) Facioscapulohumeral Muscular Dystrophy. Neurotherapeutics 5: 601. https://doi.org/10.1016/j.nurt.2008.07.005
|
| [33] |
Rogozinski BM, Davids JR, Davis RB, et al. (2009) The efficacy of the floor-reaction ankle-foot orthosis in children with cerebral palsy. J Bone Joint Surg Am 91: 2440-2447. https://doi.org/10.2106/JBJS.H.00965
|
| [34] |
Ghoseiri K, Zucker-Levin A (2023) Long-term locked knee ankle foot orthosis use: A perspective overview of iatrogenic biomechanical and physiological perils. Front Rehabil Sci 4: 1138792. https://doi.org/10.3389/fresc.2023.1138792
|
| [35] |
Rhee YG, Ha JH (2006) Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy. J Shoulder Elbow Surg 15: 445-450. https://doi.org/10.1016/j.jse.2005.10.015
|
| [36] |
Sansone V, Boynton J, Palenski C (1997) Use of gold weights to correct lagophthalmos in neuromuscular disease. Neurology 48: 1500-1503. https://doi.org/10.1212/wnl.48.6.1500
|
| [37] |
Das S, Chadwick BP (2016) Influence of Repressive Histone and DNA Methylation upon D4Z4 Transcription in Non-Myogenic Cells. PLoS One 11: e0160022. https://doi.org/10.1371/journal.pone.0160022
|
| [38] |
Lemmers RJLF, Tawil R, Petek LM, et al. (2012) Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 44: 1370-1374. https://doi.org/10.1038/ng.2454
|
| [39] |
Tihaya MS, Mul K, Balog J, et al. (2023) Facioscapulohumeral muscular dystrophy: the road to targeted therapies. Nat Rev Neurol 19: 91-108. https://doi.org/10.1038/s41582-022-00762-2
|
| [40] |
Morrison DK (2012) MAP Kinase Pathways. Cold Spring Harb Perspect Biol 4: a011254. https://doi.org/10.1101/cshperspect.a011254
|
| [41] |
Brennan CM, Hill AS, St Andre M, et al. (2022) DUX4 expression activates JNK and p38 MAP kinases in myoblasts. Dis Model Mech 15: dmm049516. https://doi.org/10.1242/dmm.049516
|
| [42] |
Ma Y, Zhang L, Huang X (2014) Genome modification by CRISPR/Cas9. FEBS J 281: 5186-5193. https://doi.org/10.1111/febs.13110
|
| [43] |
Šikrová D, Cadar VA, Ariyurek Y, et al. (2021) Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy. Mol Ther Nucleic Acids 25: 342-354. https://doi.org/10.1016/j.omtn.2021.05.020
|
| [44] |
Himeda CL, Jones TI, Jones PL (2016) CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy. Mol Ther 24: 527-535. https://doi.org/10.1038/mt.2015.200
|
| [45] |
Goossens R, Boogaard ML van den, Lemmers RJLF, et al. (2019) Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing. J Med Genet 56: 828-837. https://doi.org/10.1136/jmedgenet-2019-106402
|
| [46] |
Himeda CL, Jones TI, Jones PL (2020) Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD. Mol Ther Methods Clin Dev 20: 298-311. https://doi.org/10.1016/j.omtm.2020.12.001
|
| [47] | Statland J, Halseth A, Zhu Y, et al. Interim Results from FORTITUDETM, a Randomized Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD (1996). [cited 2024 November 25]. Available from: https://www.aviditybiosciences.com/wp-content/uploads/2024/10/Final-NMSG-2024-FORTITUDE-Poster-16SEP24.pdf |
| [48] | Fulcrum TherapeuticsFulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (2024). [cited 2024 November 25]. Available from: https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-topline-results-phase-3-reach/ |
| [49] | PR NewswireAvidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy (2024). [cited 2024 November 25]. Available from: https://www.prnewswire.com/news-releases/avidity-announces-unprecedented-aoc-1020-data-from-phase-12-fortitude-trial-demonstrating-greater-than-50-percent-reduction-in-dux4-regulated-genes-and-trends-of-functional-improvement-in-people-living-with-facioscapulohumeral-m-302170099.html |
| [50] |
Dhuri K, Bechtold C, Quijano E, et al. (2020) Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J Clin Med 9: 2004. https://doi.org/10.3390/jcm9062004
|
| [51] |
Ansseau E, Vanderplanck C, Wauters A, et al. (2017) Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel) 8: 93. https://doi.org/10.3390/genes8030093
|
| [52] |
Mocciaro E, Runfola V, Ghezzi P, et al. (2021) DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy. Cells 10: 3322. https://doi.org/10.3390/cells10123322
|
| [53] |
Ward AJ, Norrbom M, Chun S, et al. (2014) Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Nucleic Acids Res 42: 5871-5879. https://doi.org/10.1093/nar/gku184
|
| [54] |
Sardone V, Zhou H, Muntoni F, et al. (2017) Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules 22: 563. https://doi.org/10.3390/molecules22040563
|
| [55] |
Lim KRQ, Yokota T (2023) Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells. Methods Mol Biol 2587: 197-208. https://doi.org/10.1007/978-1-0716-2772-3_12
|
| [56] |
Lu-Nguyen N, Dickson G, Malerba A, et al. (2022) Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression. Biomedicines 10: 1623. https://doi.org/10.3390/biomedicines10071623
|
| [57] |
Bouwman LF, den Hamer B, van den Heuvel A, et al. (2021) Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy. Mol Ther Nucleic Acids 26: 813-827. https://doi.org/10.1016/j.omtn.2021.09.010
|
| [58] |
Rashnonejad A, Amini-Chermahini G, Taylor NK, et al. (2020) Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes. Mol Ther Nucleic Acids 23: 476-486. https://doi.org/10.1016/j.omtn.2020.12.004
|
| [59] |
Beck SL, Yokota T (2024) Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical Landscape. Int J Mol Sci 25: 9065. https://doi.org/10.3390/ijms25169065
|
| [60] |
Collotta D, Bertocchi I, Chiapello E, et al. (2023) Antisense oligonucleotides: a novel Frontier in pharmacological strategy. Front Pharmacol 14: 1304342. https://doi.org/10.3389/fphar.2023.1304342
|
| [61] |
Otto A, Patel K (2010) Signalling and the control of skeletal muscle size. Exp Cell Res 316: 3059-3066. https://doi.org/10.1016/j.yexcr.2010.04.009
|
| [62] |
Smith RC, Lin BK (2013) Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care 7: 352-360. https://doi.org/10.1097/SPC.0000000000000013
|
| [63] | National Library of Medicine, National Center for Biotechnology Information, ClinicalTrials.govStudy of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) (2022). [cited 2024 November 25]. Available from: https://clinicaltrials.gov/study/NCT02927080 |
| [64] |
Pearsall RS, Davies MV, Cannell M, et al. (2019) Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep 9: 11392. https://doi.org/10.1038/s41598-019-47818-w
|
| [65] |
Statland JM, Campbell C, Desai U, et al. (2022) Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve 66: 50-62. https://doi.org/10.1002/mus.27558
|
| [66] | Institute of MyologyAcceleron abandons development of ACE-083 in FSH (2022). [cited 2024 November 25]. Available from: https://www.institut-myologie.org/en/2022/07/12/acceleron-abandons-development-of-ace-083-in-fsh/ |
| [67] |
Wagner KR, Fleckenstein JL, Amato AA, et al. (2008) A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63: 561-571. https://doi.org/10.1002/ana.21338
|
| [68] |
Campbell C, McMillan HJ, Mah JK, et al. (2017) Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55: 458-464. https://doi.org/10.1002/mus.25268
|
| [69] |
Wagner KR, Abdel-Hamid HZ, Mah JK, et al. (2020) Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord 30: 492-502. https://doi.org/10.1016/j.nmd.2020.05.002
|
| [70] | National Library of Medicine, National Center for Biotechnology Information, ClinicalTrials.govA Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy (MANOEUVRE) (2024). [cited 2024 November 25]. Available from: https://clinicaltrials.gov/study/NCT05548556 |
| [71] |
Azzag K, Bosnakovski D, Tungtur S, et al. (2022) Transplantation of PSC-derived myogenic progenitors counteracts disease phenotypes in FSHD mice. NPJ Regen Med 7: 43. https://doi.org/10.1038/s41536-022-00249-0
|
| [72] |
Blokhuis AM, Deenen JCW, Voermans NC, et al. (2021) The socioeconomic burden of facioscapulohumeral muscular dystrophy. J Neurol 268: 4778-4788. https://doi.org/10.1007/s00415-021-10591-w
|
| [73] | American Occupational Therapy Association.Occupational Therapy Scope of Practice. Am J Occup Ther (2021) 75: 7513410020. https://doi.org/10.5014/ajot.2021.75S3005 |
| [74] | Lu J, Yao Z, Yang Y, et al. (2019) Management strategies in facioscapulohumeral muscular dystrophy. Intractable Rare Dis Res 8: 9–13. https://doi.org/10.5582/irdr.2019.01016 |
| [75] |
Sezer S, Cup EHC, Roets-Merken LM, et al. (2022) Experiences of patients with facioscapulohumeral dystrophy with facial weakness: a qualitative study. Disabil Rehabil 44: 6775-6782. https://doi.org/10.1080/09638288.2021.1973122
|
| [76] |
Wellecke C, D'Cruz K, Winkler D, et al. (2022) Accessible design features and home modifications to improve physical housing accessibility: A mixed-methods survey of occupational therapists. Disabil Health J 15: 101281. https://doi.org/10.1016/j.dhjo.2022.101281
|
| [77] |
Essers JMN, Meijer K, Peters AA, et al. (2023) The effects of facioscapulohumeral dystrophy and dynamic arm support on upper extremity muscle coordination in functional tasks. Neuromuscul Disord 33: 651-659. https://doi.org/10.1016/j.nmd.2022.11.002
|
| [78] |
Cruz A, Callaway L, Randall M, et al. (2021) Mobile arm supports in Duchenne muscular dystrophy: a pilot study of user experience and outcomes. Disabil Rehabil Assist Technol 16: 880-889. https://doi.org/10.1080/17483107.2020.1749892
|
| [79] | Faux-Nightingale A, Kulshrestha R, Emery N, et al. (2021) Upper Limb Rehabilitation in Facioscapulohumeral Muscular Dystrophy: A Patients' Perspective. Arch Rehabil Res Clin Transl 3: 100157. https://doi.org/10.1016/j.arrct.2021.100157 |
| [80] | Hazenberg A, van Alfen N, Voet NBM, et al. (2015) Facioscapulohumeral muscular dystrophy and respiratory failure; what about the diaphragm?. Respir Med Case Rep 14: 37-39. https://doi.org/10.1016/j.rmcr.2014.12.006 |
| [81] |
Wohlgemuth M, van der Kooi EL, van Kesteren RG, et al. (2004) Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 63: 176-178. https://doi.org/10.1212/01.WNL.0000133126.86377.E8
|
| [82] |
Kilmer DD, Abresch RT, McCrory MA, et al. (1995) Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 74: S131-139. https://doi.org/10.1097/00002060-199509001-00007
|
| [83] |
Moreira S, Wood L, Smith D, et al. (2017) Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. J Neurol 264: 1271-1280. https://doi.org/10.1007/s00415-017-8525-9
|
| [84] |
Santos DB, Boussaid G, Stojkovic T, et al. (2015) Respiratory muscle dysfunction in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 25: 632-639. https://doi.org/10.1016/j.nmd.2015.04.011
|
| [85] |
LoRusso S, Johnson NE, McDermott MP, et al. (2019) Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurol 19: 224. https://doi.org/10.1186/s12883-019-1452-x
|
| [86] |
Glasser CE, Gartner MR, Wilson D, et al. (2018) Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve 57: 921-926. https://doi.org/10.1002/mus.26113
|
| [87] |
Himeda CL, Debarnot C, Homma S, et al. (2014) Myogenic Enhancers Regulate Expression of the Facioscapulohumeral Muscular Dystrophy-Associated DUX4 Gene. Mol Cell Biol 34: 1942-1955. https://doi.org/10.1128/MCB.00149-14
|
| [88] |
Lek A, Rahimov F, Jones PL, et al. (2015) Emerging preclinical animal models for FSHD. Trends Mol Med 21: 295-306. https://doi.org/10.1016/j.molmed.2015.02.011
|
| [89] |
Megalizzi D, Trastulli G, Colantoni L, et al. (2024) Deciphering the Complexity of FSHD: A Multimodal Approach as a Model for Rare Disorders. Int J Mol Sci 25: 10949. https://doi.org/10.3390/ijms252010949
|
Ubaid Ansari, Dawnica Nadora, Lauren Ong, Romteen Sedighi, Ethan Tabaie, Zaid Ansari, Meraj Alam, Burhaan Syed, Noorhan Amani, Sarah Preiss-Farzanegan. Current landscape for the management of facioscapulohumeral muscular dystrophy and emerging treatment modalities: A literature review[J]. AIMS Neuroscience, 2025, 12(2): 291-311. doi: 10.3934/Neuroscience.2025016
DownLoad: